Century Therapeutics Inc (IPSC)vsVertex Pharmaceuticals Inc (VRTX)
IPSC
Century Therapeutics Inc
$2.24
-5.49%
HEALTHCARE · Cap: $434.93M
VRTX
Vertex Pharmaceuticals Inc
$454.97
+1.42%
HEALTHCARE · Cap: $113.95B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 10894% more annual revenue ($12.00B vs $109.16M). VRTX leads profitability with a 32.9% profit margin vs -8.8%. VRTX earns a higher WallStSmart Score of 66/100 (B-).
IPSC
Avoid27
out of 100
Grade: F
VRTX
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for IPSC.
Margin of Safety
+36.5%
Fair Value
$716.04
Current Price
$454.97
$261.07 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Keeps 33 of every $100 in revenue as profit
Strong operational efficiency at 39.6%
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 23 in profit
Conservative balance sheet, low leverage
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -6.0% — below average capital efficiency
Revenue declined 100.0%
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : IPSC
The strongest argument for IPSC centers on Price/Book.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.
Bear Case : IPSC
The primary concerns for IPSC are EPS Growth, Market Cap, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
IPSC profiles as a turnaround stock while VRTX is a mature play — different risk/reward profiles.
IPSC carries more volatility with a beta of 1.72 — expect wider price swings.
VRTX is growing revenue faster at 9.5% — sustainability is the question.
VRTX generates stronger free cash flow (349M), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (66/100 vs 27/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Century Therapeutics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Century Therapeutics Inc. (Ticker: IPSC) is a pioneering biotechnology company dedicated to advancing allogenic cell therapies that aim to revolutionize cancer treatment. Leveraging its proprietary induced pluripotent stem cell (iPSC) technology, the company is developing innovative off-the-shelf therapeutic solutions designed to improve both patient outcomes and accessibility. With a strong pipeline of clinical-stage product candidates and strategic collaborations enhancing its competitive advantage, Century Therapeutics is well-positioned to drive innovation in the rapidly expanding cell therapy landscape, presenting compelling potential for clinical breakthroughs and favorable shareholder returns.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?